Autori: Rodriguez-Abreu Delvys
| Naslov | Randomized, double-blind, phase II study of tiragolumab plus atezolizumab versus placebo plus atezolizumab as first-line treatment for PD-L1-selected NSCLC (CITYSCAPE) (Meeting Abstract) |
| Autori | Rodriguez-Abreu Delvys ... Secen Nevena M ... (broj koautora 21) |
| Info | SWISS MEDICAL WEEKLY, (2020), vol. br. , Suppl. 247, str. 31S-31S |
| Ispravka | ISI/Web of Science Elečas Rang časopisa Citati: ISI/Web of Science |
| Naslov | Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE). (Meeting Abstract) |
| Autori | Rodriguez-Abreu Delvys ... Secen Nevena M ... (broj koautora 20) |
| Info | JOURNAL OF CLINICAL ONCOLOGY, (2020), vol. 38 br. 15, Suppl. S, str. - |
| Projekat | Genentech, Inc.Roche HoldingGenentech |
| Ispravka | ISI/Web of Science Elečas Rang časopisa Citati: ISI/Web of Science |
